Advanced Research Projects Agency for Health (ARPA-H)

New funding. New research. New ways to protect patients. It’s all landing in your inbox tomorrow – if you’re subscribed.  Tomorrow’s July 30 edition of ARPA-H Vitals includes:  🪙 A NEW funding opportunity on pharmaceutical safety   🧗🏽 Insights on what makes a healthcare challenge “ARPA-Hard”  ♿ Updates on RAMMP, ARPA-H's high-tech mobility device Every week, Vitals brings you inside the programs, performers, and ideas changing the future of health. Subscribe today and stay connected to the breakthroughs ARPA-H is building for patients. 📨  https://lnkd.in/ezpGfRCh

Small businesses can move fast, take risks, and turn big ideas into technologies patients can use. Recently, ARPA-H brought together our SBIR awardees to kick off work with 15 small businesses across eight states, representing up to $28 million in investment. Their proposed solutions include wearables, artificial intelligence, diagnostic tools, gene therapies, and other technologies designed to move quickly from R&D toward patient use. Learn more about the companies turning small business speed and technical ambition into health technologies that could change care for patients. https://lnkd.in/et9Y3PFj #AOTechnolgoiesLLC VoiceLove Evimero Esperto Medical Sibel Health Lief Therapeutics - the wearable for mental health Physical Sciences Inc. HelioWave Technologies Corp Halcyon Biomedical, Incorporated Memsel #GTBiosciences Insilicom NIRSense Inc #AlethiumTechnologies Quantitative BioSciences, Inc. Neil Wyant Sam Gussman-Toh Shannon Greene

Millions of patients are affected by drug recalls every year, often after unsafe medicines have already reached homes, hospitals, and pharmacy shelves. ARPA-H is launching FASTPASS, a program to screen pharmaceutical shipments in minutes, through their packaging, before a single dose reaches a patient. No field-ready tool like this exists today. ARPA-H is taking on that gap. At ports, warehouses, and distribution centers, FASTPASS could help inspectors and quality teams verify safety faster without opening every box or waiting on slow lab testing. The targets are ambitious:  ✅ 100X improvement in precision   ✅ 1,000X reduction in testing time   ✅ 250 units/hr throughput at 99.99% specificity ARPA-H is now seeking performers in sensing technology, machine learning, pharmaceutical chemistry, and hardware engineering to help build the next generation of drug safety screening. 🔗 Learn more and explore the funding opportunity: https://lnkd.in/eC-r7aE3 James Coburn

Drug safety is about to get fast-tracked. 💊 

Women’s health is ready for a new era of medicine. ARPA-H recently met with American College of Obstetricians and Gynecologists (ACOG) leadership to discuss how we can accelerate breakthroughs for women, mothers, and babies. Across ovarian health, fetal monitoring, and obstetric care, ARPA-H is investing in tools and data designed to make care smarter, faster, and more precise. Thank you, ACOG, for the conversation and shared urgency.  Learn more about our women’s health initiatives ➡️ https://lnkd.in/eNrEvw8Y Christina Davidson, MD, FACOG Rachel Tetlow Sarah B. Sandra Elaine Brooks, MD, MBA FACOG FACS Camille A. C.

UCLA is proud to be part of AEGIS (Affordable Gene Editing Therapies for Immune System Diseases of Children), a new $27.7M Advanced Research Projects Agency for Health (ARPA-H) THRIVE-funded collaboration to develop affordable, personalized gene-editing therapies for children with inborn errors of immunity (IEI). Today, only two of 500 known IEIs have approved genetic therapies, each costing over $1M per child — this team aims to bring that down to below $200,000 and the time to develop the personalized editor to below three months. Learn more: https://lnkd.in/eGF33f-p 📸: The team on the ARPA-H THRIVE-funded AEGIS project includes (from top left) Donald B. Kohn (UCLA), Michael A. Pulsipher (University of Utah/Intermountain Primary Children’s Hospital), Avni Joshi (Mayo Clinic), Alexis Komor (UC San Diego), Fyodor Urnov (Innovative Genomics Institute, University of California, Berkeley), Britt Adamson (Princeton University), Hyejin Kim (Emory University), Euan Ashley (Stanford University), and Sadik Kassim (Danaher Corp.) #CRISPR #GeneEditing #GeneTherapies #IEI #ImmuneDiseases #ResearchPowersProgress

Massachusetts General Hospital has received an award to scale genome editing for rare genetic vascular diseases. Advanced Research Projects Agency for Health (ARPA-H) has given Mass General an award, up to $25.8 million, granted as part of the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicine (THRIVE) program. This will provide up to five years of funding to execute the Vascular mEdicineS using Scalable Editing pLatform (VESSEL) program. The VESSEL team focuses specifically on researching rare genetic vasculopathies, a subset of vascular disease that cause stroke, aneurysms, and heart attacks in children. Although each individual disease is rare, more than 10,000 rare diseases exist that together affect more than 30 million Americans. Currently, there are no FDA-approved disease-modifying therapies to address the underlying genetic causes. Led by Patricia Musolino, MD, PhD, the VESSEL team includes researchers from Mass General Brigham’s Gene and Cell Therapy Institute, Center for Genomic Medicine, Neuroscience Institute, and Heart & Vascular Institute. Learn more about how the team plans to advance personalized genomic medicines: http://spklr.io/6046EPFxq

⚡ CALLING THE BUILDERS WHO RUN TOWARDS IMPOSSIBLE PROBLEMS. ARPA-H is recruiting Program Managers. No easy wins. No safe playbook. No guarantee the science will work. Your job? Tackling some of the hardest problems in human health, with a narrow window to solve them, and the chance to build programs that could change the trajectory of medicine. These are not administrative roles. Program Managers are the engine of ARPA-H. They identify the problems others have stopped trying to solve, they build a strong technical roadmap, they assemble the right teams, and they drive high-risk, high-reward work toward impact for patients. You may be the right fit if you think from first principles, move across disciplines, challenge assumptions, and believe the best science should become better medicine much faster than it does today. The work is hard. The stakes are human. The opportunity is rare. Candidates who need a predictable lane, a long runway, or permission to think bigger need not apply. If you’ve spent your career seeing what medicine could become and wondering why it hasn’t happened yet, ARPA-H wants to hear from you. https://lnkd.in/e32MUsAe 

What if hearing technology did more than turn up the volume? ARPA-H Program Manager Calvin Roberts, MD joined Federal News Network with Terry Gerton to talk about HEARING, ARPA-H’s effort to tackle one of the hardest problems in hearing loss. More than 70 million Americans have trouble hearing, and crowded rooms can still make conversation hard to follow. HEARING is pushing past amplification with AI-powered neurotechnology designed to help the brain receive what the ear can no longer clearly send. Listen to the interview to learn how ARPA-H is redefining what hearing technology can do. 👂 https://lnkd.in/ev3KDQ97

ARPA-H is delivering health breakthroughs in years, not decades.    Whether it is revolutionizing cancer care, regenerating brain cells, or combatting microplastics, no challenge is too big.     Subscribe to our Vitals newsletter to stay updated on cutting-edge science, funding opportunities, important reminders, upcoming events, and more.     The future of health isn’t waiting, and neither are we. Subscribe ➡️ https://lnkd.in/ezpGfRCh